Evaluation of myocardial iron overload using magnetic resonance imaging

Blood Transfusion

Volumn 7, Issue 3, 2009, Pages 183-187

  Mavrogeni, Sophie ^a,b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEMOSIDERIN;

BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY; CHELATION THERAPY; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; FERRITIN BLOOD LEVEL; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE BIOPSY; HEMOSIDEROSIS; HUMAN; INJECTION SITE REACTION; IRON DEPLETION; IRON OVERLOAD; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; VISUAL DISORDER;

HEART; HUMANS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; THALASSEMIA;

EID: 67749127758     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0063-08     Document Type: Review

References (39)

1. th Edition 1991; 1543-1552
2. Zurlo MG, Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassemia major. Lancet 1989; 2: 27-30. (Pubitemid 19158169)
3. Sankul D, Thakerngpal K, Parcharee P. Cardiac pathology in 76 thalassemic patients. Birth Defects 1988; 23: 177.
4. Ohene-Frempong K, Schwartz E. Clinical features of thalassemia. Pediatr Clin North Am 1980; 27: 403.
5. Dwyer J, Wood C, McNamara J, et al. Abnormalities in the immune system of children with b-thalassemia major. Clin Exp Immunol 1987; 68: 621-629 (Pubitemid 17077149)
6. Kremastinos DT, Tiniakos G, Theodorakis GN, et al. Myocarditis in b-thalassemia major. A cause for heart failure. Circulation 1995; 91: 66-71.
7. Anderson L, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in b-thalassemia. Lancet 2002; 360:516-520
8. Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol 2006; 76:183-192
9. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107:3436-3441
10. Galia M, Midiri M, Bartolotta V, et al.; Multicenter Trial Group of the Society for the Study of Thalassemia and Haemoglobinopathies. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with deferoxamine or deferiprone during a randomized multicenter prospective clinical study. Hemoglobin 2003;27:63-76.
11. Di Tucci AA, Matta G, Deplano S, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008; 93:1385-1388
12. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 2006; 30:239-249
13. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10:12.
14. Mavrogeni S, Gotsis ED, Berdousi E, et al. Myocardial and hepatic T2* magnetic resonance evaluation in exthalassemic patients after bone-marrow transplantation. Int J Cardiovasc Imaging 2007; 23: 739-745 (Pubitemid 350055697)
15. Angelucci E, Muretto P, Nicolucci, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21. (Pubitemid 35177422)
16. Crosby WH. Serum ferritin fails to indicate hemochromatosis: nothing gold can stay. N Engl J Med 1976; 294: 333-334
17. Johnston DL, Rice L, Vick W, et al. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med 1989; 87: 40-47 (Pubitemid 19179408)
18. Olivieri NF, Nathan DG, McMillan JH, et al. Survival in medically treated patients with homozygous b-thalassemia. N Engl J Med 1994; 331: 574-578
19. Kremastinos D, Rentoukas E, Mavrogeni S, et al. Left ventricular inflow pattern in b-thalassemia major. A Doppler echocardiographic study. Eur Heart J 1993; 14: 351-357
20. Guyader D, Gandon Y, Robert JY, et al. Magnetic resonance imaging and assessment of liver content in genetic hemochromatosis. J Hepatol 1992;15: 304-308
21. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307:1671-1675
22. Gomori JM, Horev G, Tamary H, et al. Hepatic iron overload: quantitative MR imaging. Radiology 1991; 179: 367-369
23. Drayer B, Burger P, Darwin R, et al. Magnetic resonance imaging of brain iron. Am J Roentgenol 1986; 147: 103-110
24. Doyle FH, Pennock JM, Banks LM, et al. Nuclear MRI of the liver. Initial experience. Am J Roentgenol 1982;138:193-200.
25. Berardino ME, Small W, Goldstein J, et al. Multiple NMR T2 relaxation values in human liver tissue. Am J Roentgenol 1983; 141: 1203-1208 (Pubitemid 14210849)
26. Brasch RC, Wesbey G, Gooding CA, Koerper M. MRI of transfusional hemosiderosis in children with thalassemia major. Radiology 1984; 15: 767-771
27. Vymazal J, Brooks RA, Zak O, et al. T1 and T2 of ferritin at different field strengths: effect on MRI. Magn Res Med 1992; 27: 368-374
28. Stark DD, Moseley ME, Bacon BR. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1995; 154: 137-142
29. Gomori J, Grossman R, Drott H. MR relaxation times and iron content of thalassemic spleens: an in vitro study. Am J Roentgenol 1988; 150: 567-569 (Pubitemid 18075394)
30. Liu P, Henkelman M, Joshi J, et al. Quantification of myocardial tissue iron contents using NMR relaxation. Validation in a novel murine thalassemia model. JACC 1992; 19: 187A, abstract 76.
31. Mavrogeni S, Markussis V, Kaklamanis L, et al. A comparison of magnetic resonance and cardiac biopsy in the evaluation of heart iron in patients with b-Thalassemia. Eur J Haematol 2005; 75: 241-247 (Pubitemid 41153105)
32. Mavrogeni S, Gotsis E, Markussis V, et al. T2 relaxation time study of iron overload in b-thalassemia. MAGMA 1998; 6: 7-12. (Pubitemid 28500263)
33. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179
34. Westwood MA, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging 2003;18: 616-620
35. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003; 18: 33-39 (Pubitemid 36791266)
36. Ramazzotti A, Pepe A, Positano V, et al. Standardized T2* map of a normal human heart to correct T2* segmental artefacts; myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patients. Hemoglobin 2008; 32: 97-107. (Pubitemid 351264527)
37. Pepe A, Positano V, Santarelli MF, et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006; 23: 662-668
38. Positano V, Pepe A, Santarelli MF, et al. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. NMR Biomed 2007; 20: 578-590 (Pubitemid 47496898)
39. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-1884 (Pubitemid 46598901)